Molina Healthcare (NYSE:MOH – Get Free Report) and Mangoceuticals (NASDAQ:MGRX – Get Free Report) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their earnings, dividends, institutional ownership, risk, profitability, analyst recommendations and valuation.
Profitability
This table compares Molina Healthcare and Mangoceuticals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Molina Healthcare | -0.02% | 3.73% | 0.97% |
| Mangoceuticals | -4,794.60% | -96.39% | -89.60% |
Valuation & Earnings
This table compares Molina Healthcare and Mangoceuticals”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Molina Healthcare | $45.43 billion | 0.23 | $472.00 million | ($0.18) | -1,109.94 |
| Mangoceuticals | $460,000.00 | 18.18 | -$20.64 million | ($1.01) | -0.38 |
Molina Healthcare has higher revenue and earnings than Mangoceuticals. Molina Healthcare is trading at a lower price-to-earnings ratio than Mangoceuticals, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Molina Healthcare has a beta of 0.75, suggesting that its share price is 25% less volatile than the S&P 500. Comparatively, Mangoceuticals has a beta of 2.1, suggesting that its share price is 110% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of current recommendations and price targets for Molina Healthcare and Mangoceuticals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Molina Healthcare | 2 | 12 | 3 | 0 | 2.06 |
| Mangoceuticals | 1 | 0 | 0 | 0 | 1.00 |
Molina Healthcare currently has a consensus price target of $202.44, indicating a potential upside of 1.33%. Given Molina Healthcare’s stronger consensus rating and higher possible upside, research analysts clearly believe Molina Healthcare is more favorable than Mangoceuticals.
Insider & Institutional Ownership
98.5% of Molina Healthcare shares are owned by institutional investors. Comparatively, 56.7% of Mangoceuticals shares are owned by institutional investors. 1.4% of Molina Healthcare shares are owned by insiders. Comparatively, 16.0% of Mangoceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Summary
Molina Healthcare beats Mangoceuticals on 10 of the 14 factors compared between the two stocks.
About Molina Healthcare
Molina Healthcare, Inc. provides managed healthcare services to low-income families and individuals under the Medicaid and Medicare programs and through the state insurance marketplaces. It operates in four segments: Medicaid, Medicare, Marketplace, and Other. The company served in across 19 states. The company was founded in 1980 and is headquartered in Long Beach, California.
About Mangoceuticals
Mangoceuticals, Inc. develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc. has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program. The company was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. is a subsidiary of Cohen Enterprises, Inc.
Receive News & Ratings for Molina Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Molina Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.
